Tissue Diagnostics Market Revenue, Emerging Trends and Forecast

The global tissue diagnostics market is expected to reach USD 4.7 billion by 2025 from USD 3.4 billion in 2020, at a CAGR of 6.5%. The growth in this market is driven by rising incidence of cancer, developing infrastructure for cancer diagnosis, the recommendation of cancer screening, availability of reimbursements, and increasing healthcare expenditure.

Request for FREE PDF Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=280675

The key players in the tissue diagnostic market include Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), ABCAM (UK), Merck KGAA (Germany), BD (US), Hologic (US), Bio Rad (US), Biomeriux (France), Sakura Fientek Japan (Japan), BioSB (US), Biogenex (US), Cell Signaling Technology (US), Histoline Laboratories (Italy), Slee Medical GMBH (Germany), Amos Scientific PTY Ltd (Australia), Jinhua Yidi Medical Appliance Co.Ltd (China), Medite GMBH (Germany), Cellpath Ltd(UK), Dipath S.P.A. (Italy).

“The consumables segment is anticipated to grow at the fastest growth rate during the forecast period”

Based on product type, the tissue diagnostics market is segmented into instruments and consumables. The consumables segment is expected to grow at the highest growth rate during the forecast period. The large market share of this segment is driven mainly by their requirement in large numbers, cost-effectiveness, and ease of use. The increasing number of reagent rental agreements is also one of the major factors to drive the growth of the consumables market globally.

“The immuno his to chemistry segment is estimated to grow at a rapid rate during the analysis period”

Based on the technology type, the tissue diagnostic market is segmented into immuno his to chemistry, in situ hybridization, digital pathology and workflow, and special staining. The immuno his to chemistry segment is estimated to register the highest CAGR during the forecast period.  This can primarily be attributed to is increasing prevalence of chronic diseases across the globe, where this technology is mostly used in tissue diagnostics.

“Asia Pacific is estimated to register the highest CAGR during the study period”

Geographically, the tissue diagnostic market is dominated by North America and followed by Europe in 2019. However,the Asia Pacific region is estimated to grow at the fastest rate during forecast to period.Economic growth in the countries of this region, large population base, rising prevalence of chronic diseases, rising standard of living, growing demand for quality medical care, increasing healthcare spending, increasing government initiatives, and rising awareness regarding the use of tissue diagnostic tests, will drive the market in the region over the forecast period.

Breakdown of Profiles of Primary Participants:

  • By Company Type: Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%
  • By Designation: C-level: 30%, Director-level: 34%, and Others: 36%
  • By Region: North America: 40%, Europe: 28%, Asia Pacific: 20%, and the Rest of the World: 12%

Research Coverage:

The report analyzes the tissue diagnostic market by product, technology, disease, end user, and region.Apart from comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by market players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

Key Benefits of Buying the Report:

This report will enable both established firms and new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help these firms garner greater market shares. Firms purchasing the report can use any1,or a combination of the below mentioned5 strategies to increase their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the products of the top players in the tissue diagnostic market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the tissue diagnostic market
  • Market Development: Detailed information about emerging markets.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue diagnostic market

Get Discount on the Latest Report @ https://www.reportsnreports.com/contacts/discount.aspx?name=280675

Table of Contents

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered For The Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Growth Forecast
2.3 Market Breakdown And Data Triangulation
2.4 Assumptions For The Study

3 Executive Summary

4 Premium Insights
4.1 Attractive Market Opportunities In The Tissue Diagnostic Market
4.2 Asia Pacific Market: By Disease
4.3 Tissue Diagnostic Market: Geographic Snapshot

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Incidence Of Cancer
5.2.1.2 Growing Healthcare Expenditure
5.2.1.3 Developing Infrastructure For Cancer Diagnosis
5.2.1.4 Recommendations For Cancer Screening
5.2.1.5 Availability Of Reimbursements
5.2.2 Restraints
5.2.2.1 High Degree Of Consolidation
5.2.3 Opportunities
5.2.3.1 Significant Opportunities In Brics Countries
5.2.3.2 Growing Demand For Personalized Medicines
5.2.3.3 Increasing Number Of Clinical Trials Pertaining To Cancer Drugs
5.2.4 Challenges
5.2.4.1 Stringent Regulatory Requirements
5.2.4.2 Lack Of Infrastructure And Low Awareness In Middle- And Low- Income Countries
5.2.4.3 Availability Of Refurbished Products
5.2.4.4 Lack Of Skilled Professionals
5.2.4.5 Product Failures And Recalls
5.2.5 Trends
5.2.5.1 Increasing Number Of Reagent Rental Agreements

6 Tissue Diagnostics Market, By Product
6.1 Introduction
6.2 Consumables
6.2.1 Antibodies
6.2.2 Kits
6.2.3 Reagents
6.2.4 Probes
6.3 Instruments
6.3.1 Slide-Staining Systems
6.3.2 Scanners
6.3.3 Tissue-Processing Systems
6.3.4 Other Instruments

7 Tissue Diagnostics Market, By Technology
7.1 Introduction
7.2 Immunohistochemistry (Ihc)
7.3 In Situ Hybridization (Ish)
7.4 Digital Pathology And Workflow Management
7.5 Special Staining

8 Tissue Diagnostics Market, By Disease
8.1 Introduction
8.2 Breast Cancer
8.3 Gastric Cancer
8.4 Lymphoma
8.5 Prostate Cancer
8.6 Non-Small Cell Lung Cancer (Nsclc)
8.7 Other Diseases

9 Tissue Diagnostics Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Research Laboratories
9.4 Pharmaceutical Companies
9.5 Contract Research Organizations
9.6 Other End Users

10 Tissue Diagnostics Market, By Region
10.1 Introduction
10.2 North America
10.2.1 Us
10.2.1.1 Us Is Expected To Be Dominant Country-Level Market For Tissue Diagnostics
10.2.2 Canada
10.2.2.1 High Prevalence Of Cancer In Canada Is Expected To Support Market Growth
10.3 Europe
10.3.1 Germany
10.3.1.1 Availability Of Reimbursements For Colorectal Cancer Screening
10.3.2 Uk
10.3.2.1 Government Initiatives To Drive The Growth In The Uk
10.3.3 France
10.3.3.1 Increasing Government Funding For Cancer Diagnosis & Prevention To Support The Market Growth
10.3.4 Italy
10.3.4.1 High Incidence Of Cancer To Support The Market Growth In Italy
10.3.5 Spain
10.3.5.1 High Incidence Of Chronic Diseases To Drive The Spanish Market
10.3.6 Rest Of Europe (Roe)
10.4 Asia Pacific
10.4.1 China
10.4.1.1 Increasing Healthcare Expenditure
10.4.2 Japan
10.4.2.1 Advanced Healthcare Infrastructure To Support Market Growth In Japan
10.4.3 India
10.4.3.1 Expanding Healthcare Sector In The Country To Drive Market Growth
10.4.4 Rest Of Asia Pacific (Roapac)
10.5 Rest Of The World (Row)
10.5.1 Latin America
10.5.1.1 Increasing Number Of Cancer Screening Programs To Support Market Growth
10.5.2 Middle East & Africa
10.5.2.1 Increasing Incidence Of Cancer In The Middle East & Africa To Support Market Growth

11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis, 2019
11.3 Competitive Scenario
11.3.1 Product Launches (2017–2020)
11.3.2 Product Approvals (2017–2020)
11.3.3 Partnerships And Collaborations (2017–2020)
11.3.4 Acquisitions (2017–2020)
11.4 Competitive Leadership Mapping (2018)
11.4.1 Vendor Inclusion Criteria
11.4.2 Visionary Leaders
11.4.3 Dynamic Differentiators
11.4.4 Emerging Companies

12 Company Profiles
(Business Overview, Products Offered, Recent Developments, Mnm View)*
12.1 Roche
12.2 Danaher
12.3 Thermo Fisher Scientific
12.4 Abbott
12.5 Agilent Technologies
12.6 Merck Kgaa
12.7 Sakura Finetek Japan
12.8 Abcam
12.9 Becton, Dickinson And Company (Bd)
12.10 Bio Sb
12.11 Biogenex
12.12 Cell Signaling Technology
12.13 Histo-Line Laboratories
12.14 Slee Medical Gmbh
12.15 Amos Scientific Pty Ltd
12.16 Jinhua Yidi Medical Appliance Co.Ltd
12.17 Medite Gmbh
12.18 Cellpath Ltd
12.19 Hologic, Inc.
12.20 Dipath S.P.A.

*Business Overview, Products Offered, Recent Developments, Mnm View Might Not Be Captured In Case Of Unlisted Companies.

Share This Post